Research article · 15 Apr 2026
Conference abstractPublished 18 Aug 2016
The dilemma of excessive T-lymphocyte suppression
Damai Specialist Hospital, Malaysia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There has been much interest in a number of renal transplant immunosuppressive agents in recent years. On the other hand, there is limited evidence to describe the efficacy and safety of the different strategies used. While significant risks exist in excessive lymphocyte suppression, alemtuzumab (AL), a humanized anti CD-52 antibody has been reported by some centres as a promising agent. A systematic review was carried out to evaluate the safety and efficacy of this monoclonal antibody. Studies which did not directly compare AL with another induction agent were excluded. Primary outcomes measured were acute rejection rate and patient survival. Other end points included were cytomegalovirus (CMV) infection rate and graft survival. Subgroup analysis was carried out to further compare the efficacy between AL, antithymocyte globulin (ATG) and interleukin antagonist (IL2A). As far as acute rejection is concern, AL is non-inferior to ATG and IL2A in the first year. Some of the studies even convincingly showed AL as a favourable agent. As there is significant heteriogeneity (I2 more than 25%), qualitative summaries were used to complement this meta-analysis. We concluded AL is comparable to ATG and IL2A in preventing acute rejection. Despite its potent immunosuppressive efficacy, existing data supports it as a safe agent within the first year of renal transplant. Repeated dosing with AL is not implicated in patients with low risk of acute rejection.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Kenneth Wu”
